Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hikma Pharmaceuticals plc

Latest From Hikma Pharmaceuticals plc

Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

C-Suite Speaks Commercial Strategies

Hikma Continues To Mull Potential To Go Alone On Xyrem

Hikma’s recently installed CEO Riad Mishlawi told a packed room at the recent Jefferies 2024 London Healthcare Conference that Hikma had not reached a decision on pursuing its Xyrem ANDA product.

Generic Drugs Strategy

Hyloris And Hikma Get Maxigesic IV Approval In US

Hyloris has announced US FDA approval for its Maxigesic IV innovative paracetamol/ibuprofen solution for infusion. The product is expected to launch in the US in early 2024 via marketing partner Hikma, under the name Combogesic IV.

Approvals Value-Added Medicines

Winlevi Attracts Interest From Multiple Industry Players

As Sun Pharma announces a Canadian launch for its licensed Winlevi clascoterone cream dermatology asset, the firm’s originating partner Cassiopea has struck further deals with Hikma and Glenmark for the acne treatment to be sold in Europe, the MENA region and South Africa.

Deals Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Custopharm, Inc.
    • EIMC United Pharmaceuticals
    • Roxane Laboratories, Inc.
    • West-Ward Pharmaceuticals Corp.